Liraglutide reduces A1C to a greater extent than sitagliptin regardless of baseline A1C levels

Results: In a 26-week, randomized, open-label, active-comparator, parallel-group trial in patients with type 2 diabetes treated with ≥1500mg of metformin and with baseline A1c levels between 7.5 and 10.0%, once-daily liraglutide 1.8 mg treatment significantly reduced mean A1c from baseline (8.5%) more than sitagliptin 100 mg: -1.5% vs. -0.9%, respectively, p<0.0001. Additionally, more participants achieved A1c <7.0% with liraglutide than sitagliptin (55% vs. 22%, respectively, p<0.0001). A post-hoc analysis was conducted to examine the impact of baseline A1c on the level of glycemic control achieved with liraglutide 1.8 mg (n=218) and sitagliptin (n=219). In this analysis, patients were split into 5 categories according to baseline A1c levels: ≤7.5%, >7.5-8.0%, >8.0-8.5%, >8.5-9.0%, >9.0%. Change in A1c from baseline to week 26 by baseline A1c category were determined with ANCOVA analysis of the LOCF ITT population. Liraglutide and sitagliptin improved glycemic control across all baseline A1c categories, with greater reductions at higher baseline A1c levels (Figure). The reductions ranged from 0.9% for liraglutide and 0.2 for sitagliptin in the ≤7.5% category to 2.3% and 1.4%, respectively, in the >9.0% category. For the five A1c categories, mean A1c values at 26 weeks for liraglutide 1.8 mg were 6.5%, 6.7%, 7.0%, 7.4% and 7.3%, respectively, and for sitagliptin were 7.2%, 7.2%, 7.5%, 7.7%, 8.2%, respectively. On average, patients on sitagliptin did not achieve target A1c, even at the lowest A1c stratum, whereas liraglutide more successfully reduced patients to A1c ≤7% across several baseline A1c categories. (Figure Presented).